Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-232 vs ripasudil in primary open-angle glaucoma and ocular hypertension (phase 3, Japan)
jRCT2080225065Phase 3Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of K-232 in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Intraocular pressure-lowering efficacy of K-232 vs ripasudil. Started Feb 2020; status: completed.
02
Drugs
K-232
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2080225065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225065.